Pearce IP BioBlast™: w/e 31 July 2020

by , | Aug 3, 2020

Significant biosimilar activities this week include

27 Jul 20 | EU | Celltrion announced the European Commission has granted marketing authorisation for Remsima® (biosimilar infliximab) subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.

27 Jul 20 | The Centre for Biosimilars reported a study presented at the American Academy of Dermatology’s Virtual Meeting Experience 2020 which demonstrated  the safety, efficacy and immunogenicity of Boehringer Ingelheim’s Cyltezo® (biosimilar adalimumab) is comparable to AbbVie’s Humira®.

28 Jul 20 | Pfizer released its Q2 FY20  financial results.  Pfizer reported a 16% decrease in international revenues for Enbrel® (etanercept), attributing this decrease to biosimilar competition in Europe, Japan and Brazil.  Pfizer also revealed that it plans to launch Nyvepria® (biosimilar pegfilgrastim) in the US later this year.

28 Jul 20 | Amgen released its Q2 FY20 financial results.  Amgen reported the following impact to biologics/biosimilars global sales:

  • 6% year-over-year decrease for Prolia® (denosumab)
  • 9% year-over-year decrease for Enbrel® (etanercept)
  • 28% quarter-over-quarter decrease for Amgevita® (biosimilar adalimumab)
  • 28% year-over-year decrease for Neulasta (pegfilgrastim)
  • 35% year-over-year decrease for Neupogen® (filgrastim)
  • 28% year-over-year decrease for Epogen® (epoetin alfa)
  • 11% decrease year-over-year for Aranesp® (darbepoetin alfa)

These decreases were attributed to a range of factors including competition, COVID-19 impacts and lower net selling prices.

29 Jul 20 | EU | Shanghai Henlius Biotech and Accord Healthcare jointly announced the European Commission has approved Zercepac® (biosimilar trastuzumab) for the treatment of HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer.

30 Jul 20 | IN | Cadila Pharmaceuticals announced it has launched Ritucad® (biosimilar rituximab).  Ritucad® has been approved for Non-Hodgkin’s Lymphoma and rheumatoid arthritis.  This follows Cadila’s launch of Bevaro® (biosimilar bevacizumab) in India last week.

30 Jul 20 | US | Janssen announced the FDA approved an additional indication for Stelara® (ustekinumab) for paediatric patients with skin lesions or moderate to severe plaque psoriasis.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News